Conoah and Nuocheng Jianhua jointly announced a licensing agreement with Prolium for CD20xCD3 bispecific antibodies

On January 20th, JIN10 News reported that Connoa and NovaQuest jointly announced that the two companies and their joint venture have reached a licensing agreement with Prolium Bioscience, authorizing Prolium to develop and commercialize the CD20×CD3 bispecific antibody ICP-B02 (CM355). According to the protocol, Prolium will have the rights to develop, register, produce, and commercialize ICP-B02 in the global non-oncology field and the oncology field outside of Asia. NovaQuest and Connoa will receive a total payment of up to $520 million, including upfront and near-term payments, as well as additional payments for achieving clinical development, registration, and commercialization milestones, and both parties will receive a minority equity stake in Prolium. In addition, NovaQuest and Connoa will also receive tiered royalty payments based on future net sales of the product.